C. Mettlin et al., Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer, PROSTATE, 39(3), 1999, pp. 153-158
BACKGROUND. Measurement of the free fraction of total prostate-specific ant
igen (fPSA%) has been proposed as a useful addition to total PSA for the de
tection of prostate cancer.
METHODS. We assessed the performance of fPSA% in differentiating men with p
rostate cancer from men without cancer in a group of 1,709 subjects studied
in five institutions.
RESULTS. On the basis of PSA testing, digital rectal examination, and ultra
sound examination conducted at one or more visits, 229 cancers were diagnos
ed. The mean fPSA% in men with cancer was 9.1% compared to 18.9% in men wit
hout cancer. The fPSA% varied by age, with men under 60 having a mean fPSA
of 13.9% compared to 17.5% in men 60-69 years old and 19.8% in men over age
70. Significant associations of fPSA% with gland volume and PSA level were
also observed. The sensitivity, specificity, and positive predictive value
of different fPSA% cutoff levels were assessed in 513 men who underwent se
xtant biopsy. Sensitivity of 85.4%, 32.1% specificity, and a 39.2% positive
predictive value were observed using an fPSA cutoff of 15% in men with PSA
in the 4.0-9.9 ng/ml range. Sensitivity of 96.9%, 12.3% specificity, and a
36.2% positive predictive value were observed using an fPSA cutoff of 20%
in the same men. If 15% fPSA had been used as a biopsy criterion in men wit
h PSA of 4.0-9.9 ng/ml, the number of biopsies performed could have been re
duced by 21.2%, with a concomitant reduction in cancer detection of 14.6%.
Using a 20% fPSA criterion, biopsies would have been reduced 12.7%, with a
3.1% reduction in cancer detection.
CONCLUSIONS. These results provide some evidence that the detection of pros
tate cancer is enhanced by measuring fPSA% in addition to the established m
easure of total PSA level. Further research is needed to identify other mar
kers that have better sensitivity and specificity. (C) 1999 Wiley-Liss, Inc
.